Résumé
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.
| langue originale | Anglais |
|---|---|
| Pages (de - à) | 1475-1484 |
| Nombre de pages | 10 |
| journal | Annals of Oncology |
| Volume | 25 |
| Numéro de publication | 8 |
| Les DOIs | |
| état | Publié - 1 août 2014 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Annals of Oncology, Vol 25, Numéro 8, 01.08.2014, p. 1475-1484.
Résultats de recherche: Contribution à un journal › Article › Revue par des pairs
TY - JOUR
T1 - 2nd ESMO Consensus Conference on Lung Cancer
T2 - Non-small-cell lung cancer first-line/second and further lines in advanced disease
AU - Besse, Benjamin
AU - Adjei, A.
AU - Baas, P.
AU - Meldgaard, P.
AU - Nicolson, M.
AU - Paz-Ares, L.
AU - Reck, M.
AU - Smit, E. F.
AU - Syrigos, Konstantinos
AU - Stahel, R.
AU - Felip, E.
AU - Peters, S.
AU - Kerr, Keith
AU - Vansteenkiste, Johan
AU - Eberhardt, Wilfried
AU - Edelman, Martin
AU - Mok, Tony
AU - O'Byrne, Ken
AU - Novello, Silvia
AU - Bubendorf, Lukas
AU - Marchetti, Antonio
AU - Baas, Paul
AU - Reck, Martin
AU - Meldgaard, Peter
AU - Adjei, Alex
AU - Nicolson, Marianne
AU - Crinò, Lucio
AU - Van Schil, Paul
AU - Senan, Suresh
AU - Faivre-Finn, Corinne
AU - Rocco, Gaetano
AU - Veronesi, Giulia
AU - Douillard, Jean Yves
AU - Lim, Eric
AU - Dooms, Christophe
AU - Weder, Walter
AU - De Ruysscher, Dirk
AU - Le Pechoux, Cecile
AU - De Leyn, Paul
AU - Westeel, Virginie
N1 - Funding Information: RS has reported Consultancy/honoraria: Abbott, Amgen, Astellas, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Genentech, Eli Lilly, Roche. EF has reported Consultancy/ honoraria: Lilly, GlaxoSmithKline, Pfizer, Roche, Boehringer Ingelheim. SP has reported Consultancy/honoraria: Roche, Eli Lilly, AstraZeneca, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Serono, Daiichi-Sankyo, Tesaro. KK has reported Speakers’ bureau: Abbott Diagnostics, Roche, AstraZeneca, Eli Lilly, Pfizer. BB has reported Research grants: Pfizer, Roche, Boehringer Ingelheim, AstraZeneca. JV has reported that he is the Eli Lilly Chair in Respiratory Oncology at the Leuven University (research funding) and is the AstraZeneca Chair in Personalised Lung Cancer Care at the Leuven University (research funding). WE has reported Advisory board: GlaxoSmithKline, Amgen, Novartis, Merck, Teva, Roche, AstraZeneca, Lilly, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb; Speakers’ bureau: Roche, AstraZeneca, Lilly, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Amgen, Novartis, Hexal, Merck; Research grants: Eli Lilly. ME has reported Advisory board and/or research funding: Genentech, Boehringer Ingelheim, Lilly, Endocyte. PB has reported Research grants: Pfizer. MR has reported Advisory board: Hoffmann-La Roche, Lilly, Pfizer, AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo; Speakers’ honoraria: Hoffmann-La Roche, Lilly, Pfizer, Bristol-Myers Squibb, AstraZeneca, Daiichi-Sankyo. LP-A has reported Scientific advisor/ Speakers’ bureau: Lilly, Roche, Pfizer, Merck, Boehringer Ingelheim, Desi pharma, Celgene. PM has reported Speakers’ bureau: Roche. MN has reported Speakers’ bureau: Roche, Lilly, Boehringer Ingelheim, Pfizer, Otsuka; Research grants: Roche, Lilly, Boehringer Ingelheim, Pfizer, Novartis. SS has reported Research grants and honoraria: Varian Medical Systems; member of phase III trial management group conducted by Lilly Oncology. CF-F has reported Research grants AstraZeneca, Eli Lilly. GR has reported Speakers’ bureau/grants: Covidien. EL has reported Research support: ScreenCell and PointHope; previously Speakers’ bureau for Roche and Imedex and Advisory board for Strategen, Abbott Molecular and GlaxoSmithKline; patent pending with Clearbridge BioMedics; stock in Pfizer. VW has reported Consultancy/honoraria: Lilly, Roche, Boehringer Ingelheim and AstraZeneca (for lectures); Advisory role: Lilly, Roche and AstraZeneca; currently conducting research sponsored by Merck Serono. TM has reported: Speakers’ bureau and Honoraria from: AstraZeneca, Roche, Eli Lilly, Merck Serono, Eisai, Bristol-Myers Squibb, BeiGene, AVEO, Pfizer, Taiho, Boehringer Ingelheim, GlaxoSmithKline Biologicals, Clovis Oncology; Research funding from AstraZeneca. LB has reported Speakers’ honoraria: Pfizer, Roche, and Abbott Molecular, Inc.; research supported by and stock held in Roche. SN, AM, KS, EFS, AA, PVS, J-YD, WW, DDR, CLP, PDL, GV and CD have declared no potential conflicts of interest. LC and KO’B have not reported any potential conflicts of interest.
PY - 2014/8/1
Y1 - 2014/8/1
N2 - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.
AB - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.
KW - Consensus
KW - Esmo
KW - Further lines
KW - Non-small-cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84905195418&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdu123
DO - 10.1093/annonc/mdu123
M3 - Article
C2 - 24669016
AN - SCOPUS:84905195418
SN - 0923-7534
VL - 25
SP - 1475
EP - 1484
JO - Annals of Oncology
JF - Annals of Oncology
IS - 8
ER -